Mostra el registre parcial de l'element
dc.contributor.author | Garcia Llorens, Guillem | |
dc.contributor.author | Martínez Sena, Teresa | |
dc.contributor.author | Pareja Ibars, Eugenia | |
dc.contributor.author | Tolosa Pardo, Laia | |
dc.contributor.author | Castell, José V. | |
dc.contributor.author | Bort Martí, Roque | |
dc.date.accessioned | 2023-05-30T17:10:57Z | |
dc.date.available | 2023-05-30T17:10:57Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Garcia Llorens, Guillem Martínez Sena, Teresa Pareja Ibars, Eugenia Tolosa Pardo, Laia Castell, José V. Bort Martí, Roque 2023 A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies. Stem Cell Research & Therapy 14 1 94 | |
dc.identifier.uri | https://hdl.handle.net/10550/87131 | |
dc.description.abstract | High-throughput pharmaco-toxicological testing frequently relies on the use of established liver-derived cell lines, such as HepG2 cells. However, these cells often display limited hepatic phenotype and features of neoplastic transformation that may bias the interpretation of the results. Alternate models based on primary cultures or differentiated pluripotent stem cells are costly to handle and difficult to implement in high-throughput screening platforms. Thus, cells without malignant traits, optimal differentiation pattern, producible in large and homogeneous amounts and with patient-specific phenotypes would be desirable. | |
dc.language.iso | eng | |
dc.relation.ispartof | Stem Cell Research & Therapy, 2023, vol. 14, num. 1, p. 94 | |
dc.subject | Química farmacèutica | |
dc.title | A robust reprogramming strategy for generating hepatocyte-like cells usable in pharmaco-toxicological studies. | |
dc.type | journal article | |
dc.date.updated | 2023-05-30T17:10:58Z | |
dc.identifier.doi | 10.1186/s13287-023-03311-w | |
dc.identifier.idgrec | 159552 | |
dc.rights.accessRights | open access |